Brief: Celltrion Launches Human Clinical Trial Of Potential Covid-19 Antiviral Antibody Treatment Following Positive Pre-Clinical Results
July 17 (Reuters) - Celltrion Inc 068270.KS :
* CELLTRION LAUNCHES HUMAN CLINICAL TRIAL OF POTENTIAL
COVID-19
ANTIVIRAL ANTIBODY TREATMENT FOLLOWING POSITIVE PRE-CLINICAL
RESULTS
* CELLTRION GROUP - PHASE I STUDY OF COVID-19 ANTIVIRAL
ANTIBODY
TREATMENT CANDIDATE IN HEALTHY VOLUNTEERS IS SET FOR COMPLETION
BY Q3
* CELLTRION GROUP - ANTICIPATES PROMISING PRELIMINARY
RESULTS FROM
PIVOTAL STUDIES IN MILD, MODERATE COVID-19 PATIENTS BY END OF
YEAR
* CELLTRION GROUP - FURTHER HUMAN STUDIES ACROSS EUROPE
INCLUDING
UK ARE PLANNED
Source text for Eikon: ID:nBw8M4L5Na
Further company coverage: 068270.KS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Celltrion Healthcare Co
See all newsBrief: Celltrion USA says Ventegra Will Place FDA-Approved Biosimilar To Avastin , Vegzelma On Its Commercial Formulary As A Preferred Brand
Brief: Celltrion Healthcare To Acquire 92.7 Billion Won Worth Of Own Shares
Brief: Celltrion Healthcare Q3 Operating Profit 50.5 Billion Won, Down 30.4% From Year Earlier
Brief: Celltrion Usa- Announces Distribution And Incorporation Of Yuflyma (Adalimumab-Aaty) To Carepartners Specialty Pharmacy Cost Savings Programs
Brief: Celltrion Healthcare's Merger With Celltrion Approved In Shareholder Meeting -Yonhap